ClinicalTrials.gg
CompletedNCT02209454Updated Jul 9, 2015Results posted

Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations

A Phase 1 interventional study of Enantyum® oral solution and Keral® tablet in Acute Pain, sponsored by Menarini Group. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-09.

Sponsored by Menarini Group · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Acute Pain with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Acute Pain · United Kingdom.

Enrollment
10th of 10
26 · median 127
Started
2014
the only one that year
Phase 1
2 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
2 of 13
Menarini Group

Among the 13 studies in Acute Pain with a site in United Kingdom, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 1, and was the 3rd registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

2 of the 13 studies in Acute Pain with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute Pain with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to compare the bioavailability of 25 mg DKP.TRIS given as an Enantyum® oral solution (Test formulation) and Keral® tablet (Reference formulation). In addition, this study intends to evaluate the safety and tolerability of Test and Reference formulations.

Read the detailed description

The study was conducted in 1 site and included 26 successfully screened and randomized healthy subjects(12 female and 14 male).

The study consisted of:

  • Screening Visit (performed within 3 weeks prior to 1st PK study session), for the evaluation of study eligibility.
  • Two pharmacokinetic (PK) study sessions, separated by a minimum of a 7 day washout period, including the administration of one out of 2 study treatments at each study session (namely 25mg DKP.TRIS given as Enantyum® oral solution or Keral® tablet) according to the sequence as per randomisation list, and blood sampling for PK assessment on plasma at pre-defined time up to 24 hours post-dose.
  • End of Study Visit (7-10 days after last treatment administration).
03

Conditions studied

  • Acute Pain

Browse trials for

Keywords

  • Dexketoprofen
  • Bioavailability
  • Comparative
  • Pharmacokinetic
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between 18 to 50 years old, with a (BMI) between 18 Kg/m2 and 28 Kg/m2-

Exclusion criteria

Exclusion Criteria:

  • History of previous allergy idiosyncrasy / sensitivity to DKP.TRIS or other NSAIDs (aspirin, ibuprofen etc).
  • Any condition which might interfere with the absorption, distribution, metabolism or excretion of the drugs.
  • Surgery within previous 6 months, or blood loss > 400 mL within previous 3 months.
  • Subject with positive (HIV), surface antigen (Hep B) and virus antibody (Hep C) results.
  • History of alcohol, medicine or drug abuse.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Other
    Enantyum® oral solution

    25mg DKP.TRIS oral solution

    Drug: Enantyum® oral solution

  • Other
    Keral® tablet

    25mg DKP.TRIS tablet

    Drug: Keral® tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 133.00% for Cmax.

    Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

  2. AUC(0-t)

    The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 125.00% for AUC(0-t).

    Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

Secondary outcomes

  1. AUC(0-∞)

    AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.

    Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

  2. Tmax

    AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax).

    Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

  3. t1/2

    AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.

    Time frame: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

07

Results

Posted Jul 9, 2015

Participant flow

First Period
Participant flow — First Period
MilestoneReference IMP First, Then Test IMPTest IMP First, Then Reference IMP
Started1313
Completed1313
Not completed00
Washout Period a Minimum of a 7 Day
Participant flow — Washout Period a Minimum of a 7 Day
MilestoneReference IMP First, Then Test IMPTest IMP First, Then Reference IMP
Started1313
Completed1313
Not completed00
Second Period
Participant flow — Second Period
MilestoneReference IMP First, Then Test IMPTest IMP First, Then Reference IMP
Started1313
Completed1213
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryCmax

The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 133.00% for Cmax.

Time frame:
Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
Reported as:
Geometric mean · ng/mL
Cmax
ng/mLEnantyum® Oral SolutionKeral® Tablet
Cmax3290.70 (2996.00 to 3614.40)2785.90 (2493.20 to 3113.00)
SecondaryAUC(0-∞)

AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.

Time frame:
Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
Reported as:
Geometric mean · h*ng/mL
AUC(0-∞)
h*ng/mLEnantyum® Oral SolutionKeral® Tablet
AUC(0-∞)3473.00 (3087.70 to 3906.40)3485.60 (3135.30 to 3875.00)
PrimaryAUC(0-t)

The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 125.00% for AUC(0-t).

Time frame:
Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
Reported as:
Geometric mean · h*ng/mL
AUC(0-t)
h*ng/mLEnantyum® Oral SolutionKeral® Tablet
AUC(0-t)3362.20 (2986.20 to 3785.60)3372.00 (3027.30 to 3755.90)
SecondaryTmax

AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax).

Time frame:
Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
Reported as:
Median · h
Tmax
hEnantyum® Oral SolutionKeral® Tablet
Tmax0.25 (0.17 to 0.67)0.50 (0.25 to 1.25)
Secondaryt1/2

AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively.

Time frame:
Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).
Reported as:
Geometric mean · h
t1/2
hEnantyum® Oral SolutionKeral® Tablet
t1/21.34 (1.23 to 1.45)1.30 (1.20 to 1.41)

Adverse events

Collected over from Screening Visit to End of Study Visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enantyum® Oral Solution—0/25 (0%)4/25 (16%)
Keral® Tablet—0/26 (0%)7/26 (26.9%)
Most frequent other events
Most frequent other events
EventEnantyum® Oral SolutionKeral® Tablet
Hepatic enzyme increasedInvestigations1/250/26
Serum ferritin decreasesInvestigations1/250/26
HeadacheNervous system disorders1/251/26
SyncopeNervous system disorders1/250/26
Abdominal pain upperGastrointestinal disorders0/251/26
PresyncopeNervous system disorders0/251/26
CoughRespiratory, thoracic and mediastinal disorders0/251/26
DysphoniaRespiratory, thoracic and mediastinal disorders0/251/26
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/251/26
SneezingRespiratory, thoracic and mediastinal disorders0/251/26

Baseline characteristics

Twenty-six (26) subjects were randomized (14 male and 12 female) for 24 to complete the study. A total of 25 subjects (13 male and 12 female) completed the study. NOTE: Treatments were administered in a crossover manner, with the same population but one healthy subjects being exposed to the Reference and Test IMP.

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean28.9 ± 6.39
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female12
Male14
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
United Kingdom26
08

Study locations

1 site
  • Simbec Research Limited
    Merthyr Tydfil, UK CF48 4DR, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of May 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2014
First posted
Aug 6, 2014
Start
Apr 2014
Primary completionActual
May 2014
CompletionActual
Jun 2014
Results first posted
Jul 9, 2015
Last update
Jul 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02209454
Lead sponsor
Menarini Group
Collaborators
Simbec Research
Responsible party
Sponsor
First posted
Aug 6, 2014
Start date
Apr 2014
Primary completion
May 2014
Completion
Jun 2014
Results posted
Jul 9, 2015
Last update
Jul 9, 2015

Study contacts

Girish Sharma, MBBS
principal investigator · Simbec Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexketoprofen

Start the discussion